< Return back to Press Releases
Bridge Announces the CRO Industry’s First China-US
Visiting Scholar Program for Its Employees
February 1, 2007 - So. San Francisco, CA
- Bridge has the CRO industry’s leading preclinical CRO training program
- Bridge announces the first CRO Specific China-US Visiting Scholar Program
February 1, 2007, S. San Francisco, CA – Bridge Global Pharmaceuticals, Inc., a global leader in preclinical drug testing with facilities in the US and China, today announced initiation of a Visiting Scholar Program for its employees. This program will provide full support for qualified US employees to relocate and cross train in Bridge’s laboratories in Beijing, China or alternatively, for its qualified China employees to cross train in its laboratories in the US.
"People, process and passion—we believe people make the company, and we believe cross technical, regulatory, scientific and cultural training in China and the US will greatly facilitate our global integration" said the President of Bridge. "We encourage it, we nurture it, we believe in it—globalization is the future and we are not just talking it, we are living and evolving it- Bridge intends to lead this industry, and quite simply, our employees drive Bridge".
Training of its technical staff is a top priority at Bridge. The Company is committed to assuring that every employee has all of the skills needed to deliver high quality results with preparation that goes well beyond just the basic requirements outlined in industry regulations. All laboratory employees spend their first 3-10 weeks in training to become certified in needed technical skills. In addition, Bridge is providing its employees many other industry leading benefits, including RQAP certification in the Quality Assurance arena, support for scientists seeking DABT, DACVP, and DACLAM board certification, support for Project Management Certificates for our Study Managers, English lessons in China and Mandarin lessons in the US; China Animal Veterinarian Care Certification; AALAS and other training certifications in the US and China, and support for continuing education. Bridge is also the first proctor site for AALAS certification in China. Bridge also has in place internal instruction on unique aspects of US FDA GLP versus China SFDA GLP regulations and practices, as well as the preclinical requirement prior to the start of clinical trial in China versus in the US, as well as training and education in the best business practices in the two different countries.
"Our employees are aggressively pioneering the globalization of drug development and they are embracing it, developing it, evolving it, and in the process, transforming this industry" said the President of Bridge. "From safety testing, bioanalytical testing, procurement, project management, regulatory affairs —they are becoming industry leading globalization experts. This program is intended to develop these skills even further. The Bridge Visiting Scholar Program and other associated in house training programs provide a unique advantage to our employees, and ultimately, a huge advantage to our clients".
About Pharmaron
Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com.
|
